Abbott Laboratories Introduces 10 Clinical Chemistry Tests
01 Juin 2004 - 4:30PM
PR Newswire (US)
Abbott Laboratories Introduces 10 Clinical Chemistry Tests -Expands
Assays for Drugs of Abuse and Toxicology in Diagnostic
Laboratories- ABBOTT PARK, Ill., June 1 /PRNewswire-FirstCall/ --
Abbott Laboratories announced today the introduction of 10 assays
for drug abuse screening and toxicology including:
amphetamines/methamphetamines, barbiturates, benzodiazepines,
cannabinoids, cocaine, ethanol, methadone, opiates, phencyclidine
(PCP) and propoxyphene. Designed for use on Abbott's ARCHITECT(R)
c8000(TM), ARCHITECT(R) ci8200(TM) and AEROSET(R) Immunochemistry
Systems, these tests will be introduced and distributed worldwide.
"Clinical chemistry continues to be an important focus for our
business. These tests are critical to expanding our diagnostic test
menus as they are used by emergency departments and in a variety of
lab environments including those performing employee drug
screening," said Douglas C. Bryant, vice president, Global
Commercial Operations, Diagnostics Division, Abbott Laboratories.
"By offering these tests on multiple systems, we're able to support
today's increasing demands on the laboratory and provide them with
the flexibility, efficiency and accuracy needed to process high
volumes of patient samples." These assays, with the exception of
ethanol, utilize an Enzyme Multiplied Immunoassay Technique. This
test method uses antibodies that react with the particular drug
being detected. If the target drug is present in the sample, highly
specific antibodies attach to it and induce an optical change that
can be measured by the immunochemistry system. Ethanol is measured
through its reaction with a highly specific protein, an enzyme
called alcohol dehydrogenase. "Our clinical chemistry systems allow
laboratories to provide results quickly and process additional
tests if needed," said William Brown, Ph.D., vice president,
Diagnostic Assays and Systems Development, Abbott Laboratories.
"These particular assays provide precise and accurate results, and
they can be fully integrated into our AEROSET and ARCHITECT systems
without compromising test throughput time, providing the added
convenience of workstation consolidation." According to the United
Nations Office for Drug Control and Crime Prevention World Drug
Report 2000, it is estimated that 180 million people abuse drugs
worldwide with cannabinoids, amphetamine-type stimulants, cocaine
and opiates being the most prevalently used. About the ARCHITECT
c8000 system The ARCHITECT c8000 system can run up to 1,200
clinical chemistry tests an hour selected from a menu of 68 assays.
Multi-Dimensional Sampling (MDS) improves laboratory efficiency
with multiple sample loading of up to 217 samples via priority
(35), routine (150), and carousel (32) areas. About the ARCHITECT
ci8200 system Combining immunoassay and clinical chemistry on one
integrated platform, the ci8200 system runs up to 200 immunoassay
tests and up to 1,200 clinical chemistry tests an hour. By
consolidating both immunoassay and clinical chemistry testing
capabilities, the ci8200 helps improve laboratory productivity and
efficiency. About the AEROSET system The AEROSET clinical chemistry
system can run up to 2,000 tests per hour providing laboratories
with a high level of throughput and reduced turnaround time. This
automated system accommodates up to 230 patient samples. About
Abbott Laboratories Abbott Laboratories is a global, broad-based
health care company devoted to the discovery, development,
manufacture and marketing of pharmaceuticals and medical products,
including nutritionals, devices and diagnostics. The company
employs more than 55,000 people and markets its products in more
than 130 countries. Abbott 's news releases and other information
are available on the company's Web site at http://www.abbott.com/ .
DATASOURCE: Abbott Laboratories CONTACT: Media, Amy Woodworth,
+1-847-935-4755, or Financial Community, Christy Wistar,
+1-847-938-4475, both of Abbott Laboratories Web site:
http://www.abbott.com/ Company News On-Call:
http://www.prnewswire.com/comp/110328.html
Copyright